The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 4, pp. 556-563. DOI 10.1345/aph.1C291
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Santarlasci, B.
Right arrow Articles by Messori, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Santarlasci, B.
Right arrow Articles by Messori, A.

PSYCHIATRY

Clinical Trial Response and Dropout Rates with Olanzapine Versus Risperidone

Benedetta Santarlasci, PharmD

Researcher, Pharmacoeconomic Laboratory, Italian Society of Hospital Pharmacists, Careggi Hospital, Florence, Italy

Andrea Messori, PharmD

Head, Pharmacoeconomic Laboratory, Italian Society of Hospital Pharmacists, Careggi Hospital

Reprints: Andrea Messori PharmD, Pharmacoeconomic Laboratory, Italian Society of Hospital Pharmacists, Careggi Hospital, viale Morgagni 85, 50134 Firenze, Italy, FAX 39 055 4279738, E-mail md3439{at}mclink.it

BACKGROUND: In schizophrenia, comparing treatment dropouts between olanzapine and risperidone can be useful to better understand their relative effectiveness.

OBJECTIVE: To analyze the differences in the rates of dropout from clinical trials and response between these 2 antipsychotics.

METHODS: Literature search was based on MEDLINE (1966–May 2002). Analysis 1 included 4 randomized studies (838 patients), analysis 2 included 2 randomized studies (n = 716), and analysis 3 assessed 5 clinical studies for olanzapine (n = 928) and 3 for risperidone (n = 290). Odds ratios were estimated by the fixed-effect model.

RESULTS: The risk of treatment discontinuation (analysis 1) was significantly greater for risperidone than for olanzapine (42% vs. 33%, respectively). The response rates were identical for the 2 drugs (analysis 2). A slightly better pattern of maintenance of response was found for olanzapine (analysis 3).

CONCLUSIONS: The pattern of dropout and maintenance of remission seems to be better controlled for olanzapine than for risperidone.

Key Words: clinical trial, dropout, olanzapine, risperidone, schizophrenia

Published Online, February 28, 2003. www.theannals.com, DOI 10.1345/aph.1C291




homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.